News from aeterna zentaris inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 11, 2015, 13:35 ET

Aeterna Zentaris Announces Election of Directors at 2015 Shareholders' Meeting

QUÉBEC CITY, May 11, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announces the results...

May 07, 2015, 17:02 ET

Aeterna Zentaris Reports 1st Quarter 2015 Financial and Operating Results

Company to hold annual and special meeting of shareholders on May 8, 2015 All amounts are in US dollars QUEBEC CITY, May 7, 2015 /PRNewswire/...

May 07, 2015, 07:30 ET

Aeterna Zentaris and EMD Serono Finalize Promotional Services Agreement for Saizen® (Somatropin (rDNA origin) for Injection) in the U.S.

Aeterna Zentaris and Ascend Therapeutics® to join forces in selling EMD Serono's growth hormone deficiency therapy product QUÉBEC CITY,...

Apr 27, 2015, 16:15 ET

Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation of Phase 3 Study of Zoptarelin Doxorubicin in Advanced Endometrial Cancer

DSMB's recommendation follows 1rst interim analysis QUÉBEC CITY, April 27, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)...

Apr 23, 2015, 07:30 ET

Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc.

NEW YORK, NY, April 23, 2015 /PRNewswire/ - Crystal Research Associates, LLC announced today that it has issued an Executive Informational...

Apr 16, 2015, 07:30 ET

Aeterna Zentaris Files Additional Patent Application to Strengthen IP Protection of Zoptarelin Doxorubicin

QUÉBEC CITY, April 16, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that it has...

Apr 13, 2015, 07:30 ET

Aeterna Zentaris Announces Plans to Initiate Phase 3 Study of Macrilen™ in AGHD Following Successful Meeting with FDA

All amounts are in US dollars QUÉBEC CITY, April 13, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company")...

Mar 31, 2015, 07:30 ET

Aeterna Zentaris Signs Transfer Agreement of its Discovery Library with the Medical University of South Carolina

QUÉBEC CITY, March 31, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it has agreed...

Mar 17, 2015, 16:15 ET

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2014 Financial and Operating Results

All amounts are in US dollars QUEBEC CITY, March 17, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a...

Mar 11, 2015, 10:15 ET

Aeterna Zentaris Announces Closing of US$37 Million Public Offering of Common Shares and Warrants

QUÉBEC CITY, March 11, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the...

Mar 10, 2015, 07:30 ET

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2014 Financial and Operating Results on March 17, 2015

QUEBEC CITY, March 10, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its fourth...

Mar 06, 2015, 08:30 ET

Aeterna Zentaris Announces Pricing of US$37 Million Public Offering of Common Shares and Warrants

QUÉBEC CITY, March 6, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the...

Mar 05, 2015, 16:08 ET

Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants

QUÉBEC CITY, March 5, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that...

Jan 06, 2015, 07:30 ET

Aeterna Zentaris to Present at Upcoming Biotech Showcase Conference in San Francisco

QUÉBEC CITY, Jan. 6, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the...

Dec 29, 2014, 07:30 ET

Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research

QUÉBEC CITY, Dec. 29, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that an article...

Dec 19, 2014, 09:00 ET

Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price

QUEBEC CITY, Dec. 19, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company") announced today that it has...

Dec 01, 2014, 07:30 ET

Aeterna Zentaris and Sinopharm A-Think Sign Master Collaboration Agreement for Zoptarelin Doxorubicin in China

All amounts are in U.S. dollars QUÉBEC CITY, Dec. 1, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") and...

Nov 20, 2014, 07:30 ET

Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer

Patient recruitment in line to secure expected interim analysis in H1 2015 All amounts are in U.S. dollars (unless otherwise noted) QUÉBEC...

Nov 06, 2014, 07:00 ET

FDA Issues Complete Response Letter for Aeterna Zentaris' Macrilen™ NDA in Adult Growth Hormone Deficiency

QUÉBEC CITY, Nov. 6, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that the Company...

Nov 04, 2014, 16:30 ET

Aeterna Zentaris Reports Third Quarter 2014 Financial and Operating Results

All amounts are in US dollars QUEBEC CITY, Nov. 4, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a...